Monday, June 27, 2022
  SocialTwist Tell-a-Friend  

PARIS  , May 17, 2022 /PRNewswire/ -- ABL Europe (ABL), a pure play contract development and manufacturing organization (CDMO) specialized in development and manufacturing of virus for vaccine candidates, gene and cancer therapies and Odimma Therapeutics (Odimma) a young biotechnological company focusing on personalized cancer immunotherapy, announced that they have signed a development agreement. ABL will manufacture the viral component of Odimma's innovative and proprietary immunization platform ODI-2001. The viral component present in ODI-2001 plays the role of both a strong immune adjuvant and of a carrier for the DNA vector expressing personalized neoantigens. The GMP grade material produced by ABL will support clinical trials and early commercialization.

ABL & Odimma Therapeutics Logo

Cancer is a leading cause of death and morbidity worldwide. According to the World Health Organization, cancer burden rose to 19,3 million new cases and accounted for nearly 10 million deaths in 2020(1). One of the key challenges in the treatment of cancer is the improvement of current immunotherapies. Tailoring the medical treatment to each patient's tumor characteristics is one of the most promising approaches in the field.

Jean-Marc Limacher, MD, Chairman of Odimma Therapeutics said:

"The production of our viral component is the first pharmaceutical step in the development of ODI-2001, our personalized cancer immunotherapy ready to enter into clinic. We trust very much in the strong and historic expertise of ABL in the bioproduction of therapeutic viruses."

Patrick Mahieux, Managing Director of ABL Europe said:

"We are proud to collaborate with Odimma and leverage our long-lasting experience in viral vector manufacturing to contribute to bring solutions for the most difficult cancers to treat."

(1)  Source  : WHO, International Agency for Research on Cancer (IARC), Media Center – 15 Dec 2020 - Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020 – IARC (


ABL is a pure play contract development and manufacturing organization (CDMO) specialized in development and manufacturing of virus for vaccine candidates, gene and cancer therapies. ABL's mission is to provide GMP viral vectors from development to market, contributing to the success of its clients' immunotherapy innovations. ABL's CDMO services include bulk drug substance, fill/finish of drug product, process and assay development, and bioanalytical testing.

ABL is a subsidiary of the Institut MĂ©rieux and operates from different locations, in Europe and in the US. For more information, please visit


Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. By harnessing the ability of the patient's own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a potent next-generation personalized immunization platform. This proprietary platform has demonstrated its ability to induce a powerful cellular immune response against non-self-antigens as well as a strong anti-tumoral effect in tumor bearing mice. By design the immunization product can be produced in a short period of time and with no limits in the number of neoantigens to be targeted. For more information, visit


ABL, An Institut MĂ©rieux Company    
Justine CHABROL                        
Head of Communications & CSR

Odimma  Therapeutics,
Jessica MATTA

Logo -



More News by PR Newswire India

IAS Announces Campaign Sync Solution with Xandr's Invest DSP to Match Advertisers' Pre- and Post-bid Settings

Shahani Group Chairperson Mrs Maya Shahani Featured in The Knowledge Review's 2022 Listing of India's Most Admired Women in the Education Sector

Court Lifts Final Injunction in Favor of Altair in World Programming Case

Medvarsity partners with McGraw Hill to augment its courses and improve learning outcomes

PHD Media and 1862 OML win big at the Inkspell Media's MarTech Fest held on 24th June in New Delhi

Sigmoid strengthens financial services, industrial, and media offerings with accelerators and hiring deep domain experts

Thailand Draws on Creativity, Technology to Answer Consumer Demand for Eco-Friendly Lifestyle Goods

JOYSBIO offers SARS-COV-2 Antigen Rapid Test that detects Omicron subvariants BA.4 and BA.5

Global Secure SD-WAN Solutions Thrive as Organizations Turn to Cloud and 5G

Top 3 Countries for Future Growth Potential: The United States, Norway, and the United Kingdom

Abcam: Appointment of Vice President of Investor Relations

LIXIL announces winners and continuing support of the Asia Pacific Property Awards 2022-23

The 7th edition of the Embedded Safety & Security Summit culminated with a triumph

Myntra StyleCast rolls out Campus Ambassador Program, kick starting the journey for ~500 aspiring young creators from leading colleges

CSM Tech wins IMC Awards for transformation at JSW mines

12th DBN Science and Technology Award Ceremony to Further Broaden the Vision of Agricultural Innovation

Petal Search wins iF Award 2022, signaling its dedication to next-generation search engine

Hisense Praises Women Football Players through #RememberTheName Campaign, Commits to Enhancing Tournament Experience

CGTN: Why China's development philosophy can help promote global prosperity

Theme song "We Will Be Better" echoes 25th anniversary of HK's return to motherland

Center, States together engaged in holis...
SC to hear on Monday pleas by Shinde, re...
Jharkhand Bypolls: Cong's Shilpi Neha Ti...
Drugs worth about Rs 15 cr seized in Ass...
Apple offers students with discounts on ...
Low voter turnout in GTA polls at 57%...
 Top Stories
PM Modi inspired India to dream big... 
BCCI advises players in England to ... 
Biden walks upto PM Modi at G7 Summ... 
Trailer of Gujarati film 'Vickida N... 
Pakistan irked over BRICS meeting s... 
G7 nations unite to address evolvin... 
Dharm Guru offers puja in Indore ci... 
Formula 1 pushing towards net zero ...